Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast

Zinger Key Points
  • Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B, with 4.9% YoY growth.
  • Adjusted EPS was $1.21, topping the estimate of $1.20, driven by 8.2% organic sales growth.

On Wednesday, Abbott Laboratories ABT reported third-quarter sales of $10.64 billion, up 4.9% year over year, beating the consensus of $10.55 billion.

Organic sales growth for the underlying base business was 8.2%, led by double-digit growth in Medical Devices.

Abbott’s adjusted diluted earnings per share was $1.21, beating the analyst estimates of $1.20.

Also Read: Abbott Laboratories’ Attractive Valuation Ranks It Among Top Large-Cap MedTech Companies, Says Analyst.

“Our results this quarter demonstrate the strength of our diversified business model,” said Robert Ford, chairman and CEO of Abbott. “We’re well-positioned to achieve the upper end of our initial guidance ranges for the year and have great momentum heading into next year.”

Medical Devices sales increased 11.7% to $4.74 billion and 13.3% organically in the second quarter, including double-digit organic growth in both the U.S. and internationally. Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, Heart Failure, and Structural Heart.

Nutrition sales decreased by 0.3% to $2.07 billion (+3.4% organically), led by growth in Adult Nutrition.

Year-over-year declines in COVID-19 testing-related sales negatively impacted diagnostics sales growth in the third quarter. COVID-19 testing sales were $265 million versus $305 million a year ago.

Excluding COVID-19 testing-related sales, global Diagnostics sales increased 0.2% on a reported basis and increased 3.3% on an organic basis.

Guidance: Abbott projects full-year 2024 adjusted EPS of $4.64-$4.70 versus prior guidance of $4.61-$4.71 and consensus of $4.66.

Abbott forecasts that in the fourth quarter of 2024, the adjusted EPS will be $1.31-$1.37 versus the consensus of $1.20.

Price Action: At last check on Wednesday, ABT stock was down 0.84% to $115.07 during the premarket session.

Read Next:

Photo by Sundry Photography via Shutterstock

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareTop StoriesGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!